Overview of Celiprol

Quick Facts: Celiprolol Identity

Property	Description
Active Ingredient	Celiprolol hydrochloride
Form	Film-coated tablets
Pharmacological Class	Beta-Blocker (beta-Adrenergic Receptor Antagonist)
General Purpose	Antihypertensive and Antianginal agent
Origin/Type	Synthetic, Third-Generation, Cardio-Selective

What Type of Medication is Celiprolol?

Celiprolol is a synthetic chemical entity classified as a beta-adrenergic receptor antagonist, commonly known as a beta-blocker. The active substance in pharmaceutical preparations is Celiprolol hydrochloride, which acts by selectively modulating the body's response to stimulating hormones like adrenaline.

The drug is a third-generation beta-blocker, a classification characterized by its unique pharmacological profile. This distinction arises because the compound is cardio-selective, preferentially blocking the beta1 receptors primarily located in the heart, while simultaneously exhibiting partial stimulating activity on beta2 receptors and possessing demonstrable vasoactive properties. Celiprolol possesses Intrinsic Sympathomimetic Activity (ISA), a partial internal stimulating effect that helps maintain a more stable heart rhythm by mitigating the risk of excessively slowing the heart rate, differentiating it from pure antagonist beta-blockers.

Composition, Form, and General Purpose

Celiprolol is manufactured as a single-ingredient product designed for oral administration, typically dispensed as film-coated tablets. This solid dosage form contains the active substance, Celiprolol hydrochloride, integrated with standard pharmaceutical excipients. While marketed globally under various brands such as Celectol and Celipres, its core identity as a hydrophilic beta-blocker remains consistent.

The primary general therapeutic objective of Celiprolol is to serve as an antihypertensive and an antianginal agent. Its role involves managing blood pressure and chest discomfort, utilizing its specific ability to reduce vascular resistance. The general action helps to ease the load on the heart by supporting lower systemic blood pressure, contributing to the management of conditions characterized by elevated systemic blood pressure and effort-induced chest discomfort.

What side effects are possible with Celiprol?

Celiprol: Possible Side Effects and Safety Information

Adverse reactions to Celiprol are categorized based on their frequency of occurrence, primarily affecting the cardiovascular, nervous, and respiratory systems, as documented in governmental regulatory sources.

Adverse Reaction Scope

Common adverse reactions (may affect up to 1 in 10 people) generally include central nervous system effects such as headache, dizziness, fatigue, somnolence, and insomnia, as well as general weakness (asthenia).

Less Common or Rare effects include cardiac issues like palpitations, bronchospasm (narrowing of the airways), skin rashes, and visual disturbances. Rarely, severe psychiatric and respiratory events such as depression and hypersensitivity pneumonitis have been reported.

Serious Adverse Reactions and Safety Restrictions

Celiprol is contraindicated and should not be used in the presence of several severe, clinically significant conditions, including:

Second- or third-degree heart block and sick sinus syndrome.
Severe bradycardia (slow heart rate, typically le 50 beats per minute).
Cardiogenic shock or decompensated/uncontrolled heart failure.
Acute episodes of severe bronchial asthma or severe Chronic Obstructive Pulmonary Disease (COPD).
Severe renal impairment (creatinine clearance < 15 mL/minute).

Treatment must not be discontinued abruptly, particularly in patients with ischaemic heart disease, due to the risk of rebound effects, which can increase the frequency or severity of anginal attacks.

Population-Specific Safety Considerations

Safety requires particular caution and monitoring in specific patient populations:

Renal Impairment: A reduced dosage is necessary for patients with moderate impairment (CrCl 15-40 mL/minute), and it is not recommended for those with severe impairment.
Diabetes Mellitus: Celiprolol may mask symptoms of hypoglycemia (low blood sugar), such as rapid heartbeat, necessitating close blood glucose monitoring.
Controlled Cardiac Insufficiency: Patients must be under strict medical surveillance.
Pregnancy: Beta-blocker use near term may be associated with risks of neonatal bradycardia, hypotension, and hypoglycaemia. Its use is generally not established for pediatric patients.

Reporting to the anaesthetist is required before general anesthesia is performed.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Celiprolol overdose describes the expected physiological signs resulting from excessive beta-adrenoceptor blockade, as detailed in the authoritative prescribing information.

Domain	Documented Regulatory Statement
Documented Manifestations	Potential signs of over-ingestion include Bradycardia (abnormally slow heart rate), Hypotension (abnormally low blood pressure), and Bronchospasm (narrowing of the airways).
Severe Outcomes	Severe overdosage may lead to life-threatening conditions. Documented risks include Acute cardiac insufficiency and Cardiogenic shock resulting from profound cardiovascular system effects.
Emergency Action Required	Regulatory documents mandate that if an overdosage is suspected, the individual must contact a doctor immediately or go to the casualty department of the nearest hospital for urgent medical attention.
Supportive Management	Overdose is managed with symptomatic and supportive treatment. Documented interventions involve the Intravenous administration of Atropine for severe bradycardia and Isoprenaline treatment to counteract excessive beta-blockade.

The regulatory guidance stipulates that when interventions are necessary for severe symptoms, patient monitoring in a specialized care unit may be required to ensure continuous observation and stabilization. Treatment focuses strictly on reversing the documented physiological effects and supporting vital functions. There are no specific differential overdose notes for distinct patient populations documented in the official overdose sections.

Therapeutic Uses of Celiprol

What Celiprol Treats: Main Uses and Benefits

Celiprolol is commonly used across primary therapeutic domains involving the cardiovascular system and, in specialized contexts, vascular structural integrity.

The medication is generally used to manage mild to moderate arterial hypertension, to relieve symptoms of chronic stable angina pectoris, and to provide supportive control for certain cardiac rhythm disorders. In highly specialized care, it is also relevant for patients diagnosed with Vascular Ehlers-Danlos Syndrome (vEDS).

Management of Chronic High Blood Pressure and Strain

Celiprolol is applied in conditions characterized by periods of elevated systemic blood pressure. The use is relevant for easing the systemic burden on the heart and blood vessels. This provides support that helps ease the overall symptom burden and assists with maintaining functional stability during symptomatic periods.

“The application of this medication is relevant for easing symptoms and supports the patient during episodes of heightened discomfort.”

Relief from Effort-Induced Symptoms

The drug is commonly used in conditions characterized by recurrent, stable angina, where symptoms related to physical discomfort in the chest are typically triggered by exertion. This application is applied when appropriate to help address symptom clusters that interfere with daily functioning, offering symptomatic relief that helps patients cope more steadily with these episodes.

Quick Fact: Relief for Effort-Induced Chest Pain

Therapeutic Focus	Patient Benefit
Easing symptoms of recurrent, stable angina	Supports general well-being during symptomatic phases.
Addressing elevated systemic blood pressure	Helps ease the overall symptom burden.
Managing cardiac rhythm disorders	Assists with maintaining functional stability.
Mitigating risks in vEDS	Contributes to long-term vascular protection.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

The eligibility profile for Celiprolol is defined by regulatory bodies based on the patient’s age, pre-existing cardiac function, and organ health.

Classification	Status as Stated in Regulatory Documents
Populations for whom use is allowed	Adults are the approved population for the licensed uses (hypertension and angina pectoris).
Populations for whom use is not recommended	Paediatric population (Children/Adolescents): Use is explicitly not recommended as safety and efficacy are not established.
Populations for whom use is contraindicated	Patients with severe cardiac conditions (e.g., severe bradycardia, second/third-degree heart block, uncontrolled heart failure, cardiogenic shock, or hypotension). Patients with severe respiratory disease (e.g., acute/severe bronchial asthma) or severe renal impairment (creatinine clearance < 15 mL/minute).
Condition-specific eligibility rules	Patients with moderate renal impairment (CrCl 15–40 mL/minute) are eligible, but use is restricted and requires a mandatory dosage reduction by half and monitoring. Older Adults are permitted use but require close monitoring due to potential decreases in renal and hepatic function.
Pregnancy and lactation eligibility	Use during pregnancy is permitted but requires additional fetal growth scans and monitoring due to potential adverse effects on fetal growth. Lactation use is restricted due to unknown excretion data.

Official eligibility is strictly limited to adults who do not present any of the absolute contraindicating conditions. Conditional use is permitted only for patients with mild to moderate organ impairment, where use requires mandatory dosage adjustments and heightened medical surveillance as stipulated by the regulatory label.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Celiprolol’s officially documented interaction profile includes specific combinations classified as contraindicated, effects mediated by drug transporters, and pharmacodynamic reinforcement. All statements are based strictly on regulatory prescribing information.

Documented Exposure-Altering Interactions

The systemic exposure of Celiprolol can be significantly altered through interactions involving the P-glycoprotein (P-gp) efflux pump. Co-administration with P-gp inhibitors, such as Itraconazole, is documented to significantly increase Celiprolol plasma concentrations. Conversely, P-gp inducers like Rifampicin and the herbal product St. John's wort may lead to decreased Celiprolol concentrations. Additionally, Diuretics like Chlorthalidone and Hydrochlorothiazide are documented to reduce Celiprolol bioavailability.

Pharmacodynamic and Contraindicated Combinations

Combination Type	Example Entities	Documented Outcome
Absolute Contraindication	Intravenous Verapamil, Diltiazem, or Antiarrhythmics (e.g., Amiodarone)	Risk of profound hypotension and atrioventricular block (IV use only).
Not Recommended	Theophylline, Oral Verapamil, Oral Diltiazem	Reduced Celiprolol exposure or risk of additive cardiac effects.
Timing Requirement	Switching with Verapamil	Formal separation period is recommended.

Food and Juice Interactions

Certain citrus juices, including grapefruit juice and orange juice, are documented to cause a significant decrease in oral absorption of Celiprolol, a mechanism linked to OATP transporter inhibition. Patients are restricted from consuming these beverages.

Mechanism of Action

Celiprolol's action involves a third-generation mechanism centered on modulation of adrenergic receptors and vascular tone. The primary action is selective competitive antagonism of beta1-Adrenoceptors in the myocardium. By preventing endogenous catecholamines from fully activating these receptors, the drug modulates intracellular signaling pathways that increase heart rate and force. This molecular cascade results in a physiological reduction in the heart's rate and force of contraction.

Celiprolol is further characterized by Intrinsic Sympathomimetic Activity ( ISA), acting as a partial agonist at vascular beta2-receptors and beta3-receptors. This activity, combined with support of Nitric Oxide release, results in the expansion of peripheral blood vessels. The resulting physiological effect is a decrease in systemic vascular resistance (afterload).

Additionally, the molecule acts as an inhibitor of Renin release from the renal juxtaglomerular cells, thus engaging the humoral system. Modulating this initiating step of the Renin-Angiotensin-Aldosterone System ( RAAS) reduces the systemic formation of vasoconstrictive mediators, which contributes to a decrease in systemic vascular pressure.

Dosage and Administration Information

Celiprolol is administered exclusively through the oral route as film-coated tablets available in 200 mg and 400 mg strengths. The overall use pattern is a long-term therapy administered once daily, and the dose is typically taken in the morning, often upon rising. The tablet is scored and can be divided for adjustment purposes.

To ensure adequate absorption, the medication is ingested on an empty stomach. The dose is taken one hour before a meal or two hours after a meal with a glass of water.

The standard starting dose for adults is 200 mg once daily. Based on clinical response, the dosage may be systematically adjusted after two to four weeks, but does not exceed the maximum labeled dose of 400 mg once daily. Dosing requires specific adjustment for certain populations; for instance, the dose is reduced by half for patients with moderate renal impairment (creatinine clearance between 15 and 40 mL/minute). Use in children is generally not recommended.

When discontinuing treatment, the dosage is not stopped abruptly, but instead is gradually reduced over a period typically spanning 7 to 14 days.

Recent Clinical Evidence

Research evidence / Overview of studies for Celiprolol

Celiprolol was studied for several cardiovascular conditions, and the research available comes primarily from Randomized Controlled Trials (RCTs) and specialized studies tailored to the specific condition being investigated. This overview summarizes the research scenarios that have been explored, outlining what studies have reported and what remains uncertain.

Evidence for Use in Managing Vascular Ehlers-Danlos Syndrome (vEDS)

Research for this rare genetic condition has required specialized study designs, often utilizing open-label Randomized Controlled Trials (RCTs) supported by long-term follow-up from observational settings. These studies focused on populations consisting of adults and adolescents with genetically confirmed vEDS. The primary outcomes monitored were major events, including the incidence of acute vascular events, which are outcomes related to systemic or functional imbalance. Studies described patterns observed in the occurrence of major vascular events during the follow-up period across the groups studied. Due to the rarity of vEDS, the sample sizes were modest, and the original main trial used an open-label design, which may influence the interpretation of findings. Consequently, certainty remains low in some aspects, and data are still emerging.

Evidence for Use in Chronic Stable Angina Pectoris

Research for stable angina (effort-induced chest discomfort) is primarily made up of short-term, double-blind Randomized Controlled Trials (RCTs). These studies explored how symptoms change over time by focusing on outcomes related to physical discomfort. The main outcomes monitored were exercise capacity and the frequency of anginal attacks, which are patient-reported outcomes describing perceived discomfort. Research describes patterns where the measured changes in these symptom-related measures were observed in some studies to be comparable to those seen with other agents studied for this condition. However, follow-up durations were limited in these trials, meaning long-term effects are not fully established.

Evidence in Specific Patient Groups and Remaining Uncertainties

Research exploring Celiprolol was evaluated in numerous short- to medium-term comparative clinical trials for high blood pressure (hypertension), focusing on adult populations. Trials consistently data show patterns related to measurable reductions in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP). However, the research has not fully established how these blood pressure changes relate to long-term prevention of major cardiovascular outcomes.

Evidence in Specific Patient Groups: Research examined the populations in some common comorbid conditions, but comparative evidence is lacking for many specific subgroups, and subgroup findings are uncertain. Specific research programs for populations such as pregnant individuals or the pediatric population are either limited or non-existent in the primary regulatory filings. Overall, the level of evidence quality varies across the studies that have been conducted, and limited information is available on the durability of the response over many years.

Frequently Asked Questions (FAQ)

Common questions about Celiprol (FAQ)

Q: How does Celiprol differ from other common beta-blockers like Metoprolol?

A: According to the official product information, Celiprol is classified as a third-generation beta-blocker with a distinct pharmacological profile. It is cardio-selective, meaning it acts primarily on the heart, but it also possesses a partial internal stimulating effect (called Intrinsic Sympathomimetic Activity, or ISA) and a vasodilating action that helps blood vessels relax. These combined properties set its mechanism of action apart from many other traditional beta-blockers.

Q: Can Celiprol cause weight gain or changes to metabolism?

A: Regulatory documents do not commonly list weight gain as a frequent side effect. However, regulatory information advises caution regarding use in patients with diabetes because the medication may mask the typical symptoms of low blood sugar (hypoglycemia). The label notes that close blood glucose monitoring is specified as a precaution.

Q: Can men experience sexual side effects while taking Celiprol?

A: Official regulatory documents list adverse reactions related to sexual function. For men, these may include erectile dysfunction (difficulty getting or keeping an erection) and a decrease in libido (reduced sexual desire). These are documented effects of the medicine.

Q: What is the typical timeframe before Celiprol starts to show its effect?

A: Celiprol is a medication intended for ongoing use as a long-term treatment. The full clinical benefit, such as stabilization of blood pressure, is generally observed over a period of time. Official prescribing information suggests that the dosage is typically adjusted after two to four weeks of consistent use based on clinical response.

Q: How long does Celiprol stay in the body after taking a dose?

A: The elimination half-life of Celiprol is approximately 5 to 6 hours. This value represents the time it takes for half of the drug to be cleared from the body. Given this duration, Celiprol is designed to be taken once daily to maintain its intended effects.

Q: What happens if I forget to take a dose of Celiprol?

A: Official patient information leaflets typically provide guidance concerning a missed dose, stating the procedure if a patient remembers quickly versus when it is almost time for the next scheduled dose. The documents clearly state that a patient should not take a double dose to compensate for a missed one, as this could increase the risk of adverse effects.

Q: Is it safe to take Celiprol with common over-the-counter pain relievers?

A: Regulatory safety documents advise caution when using Celiprol alongside Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes many common over-the-counter pain relievers like ibuprofen. This combination may counteract the drug's effect by potentially reducing its blood pressure-lowering action.

Q: Are there certain foods or drinks, like grapefruit juice or alcohol, that interact with Celiprol?

A: Official interaction warnings specifically restrict the consumption of grapefruit juice and orange juice because they significantly decrease the absorption of Celiprol. Patient information indicates that the effects of alcoholic beverages should be discussed with a healthcare provider, as alcohol can increase the drug’s potential for causing low blood pressure or dizziness.

Q: Does Celiprol require any special monitoring or blood tests?

A: Regulatory documents specify that special monitoring is necessary for certain patient populations. For patients with diabetes mellitus, official guidance specifies the need for regular blood glucose monitoring. Similarly, patients with hepatic or renal insufficiency (liver or kidney problems) are subject to careful monitoring once treatment has commenced.

Q: How does Celiprol affect kidney function?

A: The drug's use is directly influenced by kidney function. For patients with moderate renal impairment (reduced kidney function), regulatory guidance mandates that the dosage is reduced by half. The drug is also formally contraindicated for use in patients with severe renal impairment (creatinine clearance less than 15 mL/ minute).

Q: Can Celiprol be taken if I have liver problems?

A: Official safety warnings indicate that patients with hepatic insufficiency (liver problems) are subject to careful monitoring once Celiprolol treatment has commenced. While dosage adjustment rules are specifically detailed for renal impairment, the need for careful monitoring in patients with liver conditions is noted in official documents.

Q: Do you need a prescription to get Celiprol?

A: Yes, Celiprol is legally classified as a Prescription-Only Medicine (POM) or equivalent in the regulatory systems where it is marketed. This means that a valid prescription from a licensed healthcare provider is required to obtain it.

Q: What are the official guidelines regarding driving while taking Celiprol?

A: Official regulatory information on the ability to drive or use machines notes that Celiprol may cause side effects such as dizziness, fatigue, and somnolence (sleepiness). The documents indicate that if these effects occur, a patient’s ability to drive or operate machinery may be impaired.

Q: Is Celiprol widely available in all countries?

A: Official marketing information indicates that Celiprol has been marketed globally under various brand names, such as Celectol and Celipres. It has received approval from several major regulatory bodies. However, its continued availability can vary significantly by country and local regulatory approval status.

Q: What have studies shown regarding Celiprolol use in patients with peripheral artery disease?

A: Official safety warnings note that Celiprol is required to be used with great caution in patients with peripheral circulatory disorders (issues with blood flow to the limbs). The warnings note that beta-blockers may potentially aggravate these conditions, and close medical monitoring is therefore specified.

Q: Can Celiprolol be used for anxiety or tremors?

A: According to official regulatory documents, Celiprol is only approved and licensed for the treatment of hypertension (high blood pressure) and chronic stable angina pectoris (chest pain). Regulatory documents do not list anxiety or tremor as approved therapeutic indications.

Q: How does Celiprol compare to newer heart medications?

A: In clinical trials for stable angina, research showed that the changes observed in symptom-related measures were, in some studies, comparable to those seen with other agents studied for this condition. Regulatory documents do not contain comparative statements that claim superiority over newer drug classes.

Q: What is the general advice for patients if they experience an adverse reaction to Celiprol?

A: Official documentation states that a patient should contact a doctor, pharmacist, or nurse if they experience any side effects or adverse reactions. The reporting of suspected adverse reactions is required by regulatory bodies, often through local reporting systems.

Q: Can Celiprol cause allergic reactions?

A: Yes, official safety information states that hypersensitivity (allergic reaction) to Celiprol or its ingredients is a formal contraindication. Official safety warnings describe the procedure for signs of a severe allergic reaction, such as a rash, swelling, or difficulty breathing, noting that immediate medical assistance is necessary.

How should Celiprol be stored and disposed of?

How to Store and Dispose of Celiprol: Official Regulatory Requirements

Official regulatory documents define specific, non-advisory rules for storing and disposing of Celiprol tablets to ensure product stability and safety.

Storage Requirements

Requirement	Official Statement
Temperature Limit	Store below 25 C
Packaging	Keep the product in the original package
Child Safety	Store out of the sight and reach of children

Celiprol has an officially documented shelf life of 3 years when stored in its original packaging within the mandated temperature range. This storage method protects the tablets from light and moisture.

Disposal Instructions

Requirement	Official Statement
General Rule	Dispose of unused product in accordance with local requirements
Special Handling	No special requirements are documented for the disposal of the used medicinal product or waste materials.

Unused or expired Celiprol should not be placed in household waste or flushed unless specifically instructed by a medicine take-back program.

Celiprol